Results 61 to 70 of about 51,276 (310)
Frontiers in Cardiovascular Medicine, 2022 ObjectiveTo compare the clinical benefits of rivaroxaban and warfarin in patients with non-valvular atrial fibrillation (NVAF) with high bleeding risk.MethodsA retrospective study was conducted on patients with high bleeding risk NVAF who were ...
Peng-Hui Liu +6 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Overview of a multi‐omics based drug repurposing strategy. The systematic drug repurposing strategy included the following steps: (1) osteoporosis driver signaling networks were identified from multi‐omics data; (2) drug functional modules were obtained using a network fusion approach to integrate drug similarity information; (3) all drugs were ranked ...
Dan‐Yang Liu +21 more
wiley +1 more source
Clinical Medicine Insights: Case Reports, 2015 Rivaroxaban is an orally active direct factor Xa inhibitor used to treat venous thromboembolism with approved starting dose of 15 mg twice-daily. We present a case of an accidental overdose in a patient with pulmonary thromboembolism, when the patient ...
Dimitar Sajkov, Alexander Gallus
doaj +1 more source
Pharmaceutics, 2023 Apixaban and rivaroxaban have first-line use for many patients needing anticoagulation for venous thromboembolism (VTE). The pharmacokinetics of these drugs in non-obese subjects have been extensively studied, and, while changes in pharmacokinetics have ...
Cyril Leven +6 more
doaj +1 more source
Is there a role for oral triple therapy in patients with acute coronary syndromes without atrial fibrillation? [PDF]
, 2018 © 2018 Bentham Science PublishersBACKGROUND: Acute coronary syndrome (ACS) patients, despite treatment with dual antiplatelet therapy (DAPT), have up to 10% risk of recurrent major adverse cardiac events (MACE) in the short term.
Akhtar, Zaki +3 more
core +2 more sources
Discontinuation of Rivaroxaban
Journal of the American College of Cardiology, 2013 Late in 2011, rivaroxaban became the first factor Xa inhibitor to receive regulatory approval for the prevention of stroke in patients with atrial fibrillation (AF), based largely on the results of the phase III ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared ...
openaire +3 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Nonsteroidal anti‐inflammatory drugs (NSAIDs) are widely used for pain and inflammation but are associated with gastrointestinal (GI) bleeding. While this risk is well established, most studies evaluate NSAIDs as a homogenous class, limiting clinical decision‐making based on individual agent safety.
Abdelrahman G. Tawfik +7 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Overview of the implemented pharmacogenomics (PGx) process in clinical routine at the Robert Bosch Hospital: from patient enrollment via the hospital information system, DNA detection using a customized TaqMan OpenArray panel and qPCR for CNV assessment, to clinical translation of genotyping results into PGx guideline‐based recommendations using a ...
Roman Tremmel +13 more
wiley +1 more source
Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. [PDF]
, 2019 IntroductionPatient-reported outcomes (PROs) and satisfaction endpoints are increasingly important in clinical trials and may be associated with treatment adherence.
Becker, Richard C +14 more
core +1 more source
Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events [PDF]
, 2018 Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor.
Cafolla, Arturo +4 more
core +1 more source